Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders

Journal of Association of Physicians of India

Volumn 55, Issue JULY, 2007, Pages 507-510

  Agarwal, M B ^a  

^a BOMBAY HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

JAK2 PROTEIN, HUMAN; JANUS KINASE 2; UNCLASSIFIED DRUG;

GENETIC MARKER; GENETICS; HUMAN; MOLECULAR BIOLOGY; MUTATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PROGNOSIS; REVIEW; THROMBOCYTHEMIA;

GENETIC MARKERS; HUMANS; JANUS KINASE 2; MOLECULAR BIOLOGY; MUTATION; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PROGNOSIS; THROMBOCYTHEMIA, HEMORRHAGIC;

EID: 34347404121     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Damashek W. Some speculations on the myeloproliferative syndromes. Blood 1951;6:372-5.
2. Valentino L, Pierre J. JAK/STAT signal transduction : regulators and implication in haematological malignancies. Biochemical Pharmacology 2006;71:713-21.
3. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 2006;134:366-84.
4. Bartram C, de Klein A, Hagemeijer A. Translocation of c-abl oncogene correlates with the presence of the Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306:277-280.
5. Baxter EJ, Scott LM, Camphell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.
6. James C, Ugo V, Le Couedic, et al. A unique clonal JAK2 mutations leading to constitutive signaling causes polycythemia vera. Nature 2005;434:1144-8.
7. Kralovics R, Passamonti F, Buser AS et al. A gain-of-functions mutation of JAK2 is myeloproliferative disorders. N Eng J Med 2005;352:1779-90.
8. Levine RL, Wedleigh M, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.
9. Zhao R, Xing S, et al. identification of an acquired JAK2 mutation in polycythemia vera. Journal of Biol Chem 2005;280:22788-92.
10. V617F mutation in familial myeloproliferative disorders. Program and abstracts of the 2005 American Society of Haematology Annual Meeting and Exposition : December 10-13, 2005; Atlanta, Georgia. Abstract 115.
11. Teofili L, Giona F, et al. Markers of myeloproliferative disease in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007;25:1048-53.
12. V617F activity and polycythemia vera cell growth. J Biol Chem 2007;282:3428-34.